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Background: One of the frequent reasons for unsuccessful conception is premature ovarian failure/primary ovarian
insufficiency (POF/POI) that is defined as the loss of functional follicles below the age of 40 years. Among the genetic
causes the most common one involves the X chromosome, as in Turner syndrome, partial X deletion and X-autosome
translocations. Here we report a case of a 27-year-old female patient referred to genetic counselling because of
premature ovarian failure. The aim of this case study to perform molecular genetic and cytogenetic analyses in
order to identify the exact genetic background of the pathogenic phenotype.
Results: For premature ovarian failure disease diagnostics we performed the Fragile mental retardation 1 gene
analysis using Southern blot technique and Repeat Primed PCR in order to identify the relationship between the
Fragile mental retardation 1 gene premutation status and the premature ovarion failure disease. At this early onset, the
premature ovarian failure affected patient we detected one normal allele of Fragile mental retardation 1 gene and we
couldn’t verify the methylated allele, therefore we performed the cytogenetic analyses using G-banding and fluorescent
in situ hybridization methods and a high resolution molecular cytogenetic method, the array comparative genomic
hybridization technique. For this patient applying the G-banding, we identified a large deletion on the X chromosome
at the critical region (ChrX q21.31-q28) which is associated with the premature ovarian failure phenotype. In order to
detect the exact breakpoints, we used a special cytogenetic array ISCA plus CGH array and we verified a 67.355 Mb size
loss at the critical region which include total 795 genes.
Conclusions: We conclude for this case study that the karyotyping is definitely helpful in the evaluation of premature
ovarian failure patients, to identify the non submicroscopic chromosomal rearrangement, and using the array CGH
technique we can contribute to the most efficient detection and mapping of exact deletion breakpoints of the deleted
Xq region.
Keywords: Sterility, Premature premature ovarian failure (POF), Primary ovarian insufficiency (POI), FMR1 gene analysis,
Array–comparative genomic hybridization (aCGH), X chromosome deletion, Repeat primed PCR, G-banding, Deletion
breakpoint, Turner syndromeBackground
Premature ovarian failure (POF) is an ovarian defect
characterized by the premature depletion of ovarion
follicles befor the age of 40 years, and its aetiology is
still unknown in most cases. Coulon et al. examined
1858 patients with premature ovarian failure, and the
age-specific incidence was based on the results: under
40 years of age the incidence was 1:100, and under* Correspondence: beke.artur@noi1.sote.hu
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stated.30 years of age the incidence was 1:1000 [1]. In addition to
a reduction in the duration of fertility, there are other
important health issues that may be associated with POF
such as an increased risk of overall mortality, cardiovascular
diseases, osteoporosis and autoimmune disorders such as
diabetes or problems with the thyroid or adrenals [2]. In
particular, an association between POF and abnormalities
of the X chromosome has been reported several times,
and another cause, which can be associated with POF,
is the balanced X/autosomal translocations despite their
generally neutral clinical effect [3]. In fact, the breakpoints
of these aberrations are distributed over the whole Xd. This is an Open Access article distributed under the terms of the Creative
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region between Xq13 and Xq26 [4-7]. Deletion on the X
chromosome reduces both fertility and reproductive
lifespan and the basis of studies two loci for Xq-linked
POF have been postulated: deletion in POF patients
have been localised to chromosome Xq21.3-Xq27 (POF1),
while balanced X/autosome translocations have been
localised to Xq13.3-Xq21.1 (POF2) [8]. The above-
mentioned POF disorder has been attributed to various
causes including rearrangements or large deletion of
the “critical region” in the long arm of the X chromosome.
However, it is interesting that there are several genes
which have consistently found to be involved in POF on
the X chromosome and autosomes but the POF1 region
deletions are by far more commonly associated with POF
phenotype. Another abundant reason for the POF is the
single gene association that can also be involved in the
POF phenotype. Out of the single genes group, the FMR1
gene appears to be the most significant cause of POF
disease. The association between FMR1 premutation and
POF has been previously investigated at a molecular level
by analysing FMR1- related factors such as the repeat
tract size. Expansion of (CGG) triplet repeats in the
FMR1 gene is associated with several disorders, including
fragile X syndrome (FRAXA), fragile X-associated tremor/
ataxia syndrome (FXTAS), and fragile X-associated primary
ovarian insufficiency (POF). Fragile X syndrome is nearly
always characterized by moderate mental retardation in
affected males, with full mutation and FXTAS occuring in
males who have an FMR1 premutation, and is characterized
by late onset progressive cerebellar ataxia and intention
tremor. FMR1-related (with the premutation alleles,
which may have 55 to 200 CGG) POF (age at cessation
of menses <40 years) occurs in approximately 20% of
females who have an FMR1 premutation [9]. Since full
mutation carriers do not have an increased risk for
ovarian dysfunction, the molecular mechanism underlying
the association between POF and FMR1 gene premutation
alleles, although still unravelled, should not be related to
the absence or reduction of the fragile mental retardation
protein (FMRP) [10]. The known association between
POF and premutation alleles in the FMR1 gene [11]
prompted us to initiate fragile X testing. In this case
study, we performed a detailed FMR1 gene CGG repeat
number assay and cytogenetic analysis such as FISH,
G-banding and molecular cytogenetic analysis, which are
based on the array CGH technique. The aim of this case
study was to perform molecular genetic and cytogenetic
analyses in order to identify the exact genetic background
of the pathogenic phenotype.
Case presentation
Genetic testing of the 27 year old female patient was
carried out due to suspected premature ovarian failure/primary ovarian insufficiency (POF/POI). Her menses
ceased at the age of 25. The first menses (menarche)
started at the age of 12. There is no pregnancy or
assisted reproductive procedure appearing in her history.
Other illnesses, genetic disorders, mental retardation have
never occurred in the family. The menopause of her
mother occurred at the age of 53. The patient’s body
type is average, BMI: 19.4 (average: 18.5 to 24.99). During
the examination the disease met the criteria for premature
ovarian failure/primary ovarian insufficiency (POF/POI):
secondary amenorrhea, ovarian failure before the age of
40, levels of FSH > 40 IU/l in two different measurements
and low estrogen levels. The patient has never had surgery
significantly affecting both ovaries; ovarian toxic medications
have never been used (cytostatic treatment). The patient’s
mother has normal karyotype and her father was already
deceased. For this case study we presented the details
of the molecular and cytogenetic analyses at the index
patient which were performed by G-banding; FISH,
Southern-blotting, Repeat Primed PCR and array-CGH
technique.
Methods
Chromosome and fluorescence in situ hybridization analysis
Chromosome analysis was performed on stimulated per-
ipheral blood cultures on metaphase cells with trypsin and
Wright Giemsa stain. Fluorescence in Situ Hybridization
(FISH) analysis was carried out on methanol/acetic acid-
fixed suspensions. Slide preparation for FISH was made
according to standard techniques. X, Y centromere specific
probes as well as X Painting probe (Cytocell, United King-
dom) were used for evaluation of sex chromosomes and
their possible hidden structural abnormalities. Spectrum
Green CEP X and Spectrum Red SRY gene specific probe
(Abbott, Germany) were used to detect chromosome X
copy number and to control the presence of the SRY gene
on the chromosome, respectively. Karyotypes and FISH
results were described according to the International Sys-
tem for Human Cytogenetic Nomenclature (ISCN 2013).
Southern blot
Genomic DNA from the patient was isolated from periph-
eral lymphocytes by the simple salting-out procedure.
DNA was subjected to restriction enzyme digestion with
EcoRI and the methylation sensitive enzyme EagI followed
by Southern blot analysis and hybridization using the
DNA probe StB12.3 [12]. In unaffected females, two
bands are visible: a 2.8 Kb fragment corresponding to
the unmethylated X and a 5.2 kb allele representing the
methylated X chromosome.
Repeat primed PCR
The exact number of CGG repeats was determined by
Repeat Primed PCR technology (Amplidex, Asuragene).
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then for PCR was used 2 μl. The PCR reaction was carried
out in three primers: the FMR1 gene-specific primers
(forward and reverse, FAM-labeled) and a CGG repeat
specific primer. The PCR products were separated by
size, using capillary electrophoresis. The statistical analyzes
were performed with FMR1AnalysisMacro_version 2.1.1
software and GeneMapper software.
Array CGH analysis
Array CGH analysis was performed according to the
manufacturer’s protocol on genomic DNA ISCA plus
design array of Nimblegen Roche containing 1.4 M probes
per sub array. This microarray provides a mean average
resolution of approximately 15–20 Kb on chromosomes
to detect chromosomal imbalances throughout the whole
genome. The CGH protocol involves independent label-
ling of the patient (test DNA) and the reference genomic
DNA (Human Genomic DNA, Promega Madison, WI
U.S.A.) with Cy3 and Cy5 dyes using a NimbleGen
Dual-Color DNA Labelling Kit (Roche NimbleGen Inc.).
Cohybridization of these DNAs to a NimbleGen CGH
arrays were performed for 72 hrs at 42˚C. FollowingFigure 1 G-banding analysis. The karyotype of the patient with Xq21-q28hybridisation, the array was washed and dried at room
temperature using the wash buffer kit (Roche NimbleGen
Inc.). Array CGH was scanned on NimbleGen MS 200
microarray scanner and data was extracted and analysed
using NimbleScan software and SignalMap and Deva 1.1
software (Roche NimbleGen Inc.). DNA CNVs were
mentioned as gain or loss as a linear ration, and the
length of the variation was given in megabase (Mb).
Results
For the POF/POI affected patient, the G-banded analysis
based on 30 metaphases revealed two cell lines, the
argest has a structural (Xq deletion) and the smallest a
numerical (X monosomy) chromosome abnormality. The
mosaic karyotype was the following: 46,XX,del(X)(q21q28)
[25]/45,X[5] (Figure 1). The patient’s mother has normal
karyotype and as the father was already deceased. This
deletion in a male would be incompatible with life and
so we can stated that the deletion is “de novo”. The
FISH examination with the X centromere/SRY specific
probe-based on 200 interphase cells-detected two X
chromosomes in 90% of cells and X monosomy in 10%
of cells and no SRY signals respectively (Figure 2a). Thedeletion of the dominant cell line.
Figure 2 FISH analysis. For FISH analysis using chromosome X
centromere specific probe (CEP X) which shows normal female
pattern (two green signals) in 90% of cells and X monosomy
(one green signal) in 10% of interphase cells (a). The whole painting
chromosome X (WC X) identified a normal and a smaller size red
colored X chromosome and excluded the possible X chromosome
translocation (b).
Figure 3 Picture of Southern blot analysis. EcoRI and EagI double
digested DNA samples using radioactive-labelled Stb12.3 probe for
Southern blot hybridization. Arrows indicated the 2.8 Kb unmethylated
and the 5.2 Kb methylated fragments size. For the case sample we can
define the missing 5.2 Kb methylated fragment (circle compassed). POF
283/4, POF 285/4 and POF 287/4 cases indicated those female samples
who did not carry FMR1 gene premutation and the background of the
POF phenotype should be withstand other genetic deviation. For all
these cases we identified two X chromosome normal allels (2,8 kb
unmethylated and 5.2 kb methylated).
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X chromosome balanced translocation and identified a
normal and a smaller size X chromosome in 88% and one
normal size X chromosome in 12% of cells (Figure 2b).
For southern blot in this case we detected one FMR1 allele
of X chromosome which was the 2.8 Kb size and
unmethylated, and the 5.2 Kb methylated allele was not
detected (Figure 3). For southern blot analysis for the
index patient we can detect only the active X chromosome
so this is why we had to make the Repeat-primed PCR
in order to identify the CGG number and the exact allele
number. Repeat-primed PCR analysis revealed a peak,
which corresponds to a 23-CGG, and we can detect only
one FMR1 gene allele. The method is also suitable fordetection of AGG sequences interrupting CGG repeats.
The AGG repeats stabilize the CGG repeats containing
sequences. The more the number of AGG interruptions,
the less likely it is to grow in the next generation of
the number of CGG repeats. At the index patient we
determined only one AGG interruption (Figure 4).
Regarding the result of the cytogentics analysis we
identified a large deletion on the X chromosome (measure:
67.355 Mb) and in order to identify the exact breakpoints,
we made the array CGH technique and we defined an
X chromosome loss that is located at ChrX:87842016–
155255380 (ChrX q21.31-q28) based on the Human
genome GRCh37/hg19 assembly (Figure 5).
Discussion
A 27 year old woman with premature ovarian failure
including ceased menses at the age of 25 and elevated
FSH? 40 mIU/ml and low estrogen levels. She carried a
67.355 Mb deletion on one of the X chromosomes and
the exact breakpoints boundaries were identified by an
oligonucleotide aCGH analysis. In this region, in total
795 genes were located and up until now, ten genes
(POF1B; BHLHB9; DACH2; DIAPH2, FMR1; FMR2;
XPNPEP2; PGRMC1, CENP1, BCORL1) have been
identified as the ones associated with POF (Table 1).
The frequencies of these genes in POF are different, the
Figure 4 Picture of repeat primed PCR analysis. Repeat-primed PCR analysis revealed a peak, which corresponds to a 23-CGG with only one
AGG interruption.
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cases [13,14] and followed PGRMC1 variants with 1–5%
prevalence [15] and for the other six genes the frequencies
are still unknown in POF/POI disease. The other genetic
aspect which can effect the POF/POI phenotype is the
chromosomal anomalies. These aberrations can be liable
for the POF/POI phenotype in 8.8-33% of women [16]
and 10-15% of the cases are X chromosome abnormalities,
such as numerical and structural aberrations (deletions,
inversions and X/autosome translocations) [17,18]. Theor-
etically, fertility impairment in patients with chromosomal
abnormalities can be explained in various ways. First of
all, chromosomal anomalies might disrupt a gene that
is important for gonadal function [19] and structuralFigure 5 NimbleGen ISCA plus CGX design profile for X chromosome
genomic regions with the cytogenetic bands on the X chromosome. An 67
and a black rectangle indicate the length of the loss. b.) Array-CGH workflo
one copy. The 67.355 Mb deleted chromosome segment (GRCh37/hg19; C
The blue and yellow dots depict the normalized ration on every probe on
enlarged region. d.) Next the ideogram listed genes and positions which a
we visualized some of them. We signed with bold font those genes, whichrearrangements involving the X chromosome may disrupt
the normal pairing at meiotic arrest [3]. Focus on the
candidate genes that may be implicated in the POF
phenotype, the first gene that we must exam, is the
POF1B gene. The function of this gene is still unknown,
although it binds to actin and has some homology to
myosin heavy chain, so it has a remarkable role in the
chromosome pairing procedure. This gene product is
expressed in the ovaries during early embryonic develop-
ment [20] and the mutation of the POF1B gene affects
the actin binding action that may be obligate at meiotic
chromosome pairing and apoptosis [21]. Deletion of the
other candidate gene the BCORL1 may lead to insufficient
repression of apoptosis resulting in atresia of ovarian. a.) The ideogram (below: black, grey and white bars) delineates
.355 Mb sized loss on chromosome Xq21.3-q28 for the female patient
w. The CGX ISCA plus array showed a 67.355-Mb loss which presented
hrX: 87842016–155255380) is denoted by a bar red line below zero.
the X chromosome. c.) Schematic representation of the chrXq21.3-q28
re affected this patient. This affected region contains 1818 genes and
can x play a roll to induce the POF/POI phenotype.
Table 1 POF associated genes at the critical region on chromosome X which are affected at patient
Gene
acronym
Gene name Chromosome
localisation
OMIM Phenotype Protein
POF1B Premature ovarian failure1B ChrXq21.1-q21.2 300603 Premature ovarian failure 2B This gene is expressed at trace levels in mouse prenatal
ovary and is barely detectable or absent from adult ovary,
in human and in the mouse respectively.
BHLHB9 Basic helix-loop-helix
domain-containing class B 9
ChrX q21.1 Premature ovarian failure Other members of this gene family encode proteins which function
as transcription factors, either enhancing or inhibiting transcription
depending on the activity of the DNA binding proteins.
DACH2 Drosophila dashsund ChrX q21.2 300608 Premature ovarian failure This gene is one of two genes which encode a protein similar to
the Drosophila protein dachshund, a transcription factor involved in
cell fate determination in the eye, limb and genital disc of the fly.
DIAPH2 Homologue drosophila ChrXq21.33 300108 Premature ovarian failure The product of this gene belongs to the diaphanous subfamily of
the formin homology family of proteins. This gene may play a
role in the development and normal function of the ovaries.
CENPI Centromeric protein 1 ChrXq22.1 300435 Involved in the gonadal tissue response to FSh and
assembly of the kinetochore
It has a critical role in chromosome segregation and with
deletions candidate for human X-lined disorders of gonadal
development and gametogenesis.
PGRMC1 Progesteronereceptor
memebrane component-1
ChrXq24 300435 Premature ovarian failure This gene encodes a putative membrane-associated progesterone
steroid receptor. The protein is expressed predominatly in the
liver and kidney.
BCORL 1 BCL6 Corepressor-like 1 ChrXq25-q26.1 300686 BCORL1 interacted with class II
histon deacetylases suggesting that they
are involved in its function as a corepressor
Deletion of BCORL 1 gene may potentially lead to insufficient
repressor of apoptosis resulting in atresia of ovarian follicles.
XPNPEP2 Propyl aminopeptidase ChrXq26.1 300145 Angioedema induced by ACE inhibitors,
susceptibility to
XPNPEP2, the X-linked gene that encodes membranous
aminopeptidase P (APP), has been reported to associate with APP
activity. The membrane aminopeptidase P (XPNPEP2) is largely
limited in distribution to endothelia and brush border epithelia.
FMR1 Fragile X mental retardatin 1 ChrXq27.3 309550 Fragile X syndrome Fragile X tremore/ataxia
syndrome Premature ovarian failure 1
The protein encoded by this gene binds RNA and is associated
with polysomes. The encoded protein may be involved in mRNA
trafficking from the nucleus to the cytoplasm.
FMR2/
AFF2
Fragile X mental retardation 2 ChrXq28 300806 Mentar retardation, X-linked, FRAXE type This gene encodes a putative transcriptional activator that is a
member of the AF4\FMR2 gene family.
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gene (CENP1) that has been shown to have a critical role
in chromosome segregation and the deletion of this
gene may cause cell death. It has also been suggested
that these structural abnormalities may exert an epigenetic
effect influencing the expression of X-linked or autosomal
ovary-expressed genes [22]. As the molecular study
revealed, the BCORL1 gene has a repressor activity
through an association with histone deacetylase, suggesting
that they are involved in its function as a corepressor.
Disposing the histone associated epigenetic system; the
BCORL1 gene may play a role in the epigenetic modifica-
tion but as scientific literature suggests, genes interruption
is not the major cause of pathological phenotype. In
particular the breakpoint in the X-autosome translocation
in the POF2 interval falls outside gene coding regions,
and it has been suggested that the observed effect on
expression of ovary and oocyte autosomal and X-linked
genes flanking the translocation breakpoints may arise as
a consequence of long range effects on promoter activity
[22]. Second, some of these genes can influence hormone
levels and tissue response to hormones that may impact on
efficient oocyte development and maturation. For example,
in addition to a role in centromere formation, the CENP1
gene is involved in gonadal tissue response to FSH [23].
For the index patient as we mentioned before using
the Southern blot assay, we detected a normal and active
X chromosome and the absence of the methylated FMR1
allele, according to Lyon hypotheses, should be inactivated
in 50% of cells [24]. As scientific studies described, the
haploinsuffiency of the genes, which are located in the
missing region on one of the chromosome X, could be a
promising explanation for the POF disease background,
especially when it involves Xq28. A haploinsufficient gene
is described as needing both alleles to be functional in
order to express the wild type. The lack of expression of
those missing genes that normally escape X inactivation
may threaten ovarian function [25]. Based on the scientific
studies we can conclude that with this POF, the affected
patient may be configured by abnormal X chromosome
pairing and the epigenetic modification [26]. The epi-
genetic effects would be supportable if the patient had
a POF affected relative carrying the same deletion. In
this case we confirmed a “de novo” X-chromosome dele-
tion, so we cannot make any phenotype comparison. We
conclude that cytogenetic analysis might be the first step
in the investigation of POF/POI, as it might make some
subsequent analysis steps unneccessary (i.e. Southern blot
and PCR).
Conclusion
Here we present a patient affected with POF disease,
where molecular and cytogenetic analyses revealed that
she was a carrier of a large deletion spanning fromXq21.31-q28. Sample DNA of the POF phenotype affected
women were collected so as to identify the exact molecular
genetics background. As the scientific studies suggested,
the most frequent gene mutation that can cause the POF
phenotype, is the CGG triplet repeat number increasing
which denoted that these females are the permutation
status carrier. For the index patient we confirmed a
large deletion on one of the X chromosomes and we
couldn’t detect premutation status at the FMR1 gene.
In order to identify the exact breakpoints of the X
chromosome deletion, we made the array CGH analyses.
As we verified the deletion on the database, we realised
that this deletion region consisted of 795 genes, and 10
of them were considered as POF associated genes.
Comparing the phenotype and the molecular genetic
results, we concluded that for this patient, we established
the POF1 disease and offering the prenatal diagnostic
at possible future pregnancies is crucial.
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